Real-World data on lung cancer drug dacomitinib shows promise
NCT ID NCT06321510
First seen Apr 07, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study tracks 29 adults in Taiwan with advanced lung cancer who have a specific gene change (EGFR-positive) and were treated with the oral drug dacomitinib. Researchers want to see how often people need to change their dose or stop treatment, and how long they live without the cancer getting worse. The goal is to understand how well dacomitinib works outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tri-Service General Hospital
Taipei, 11490, R.O.C., Taiwan
Conditions
Explore the condition pages connected to this study.